Literature DB >> 10751257

Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome.

C W Ang1, B C Jacobs, A H Brandenburg, J D Laman, F G van der Meché, A D Osterhaus, P A van Doorn.   

Abstract

OBJECTIVE: To investigate whether anti-GM2 antibodies in patients with Guillain-Barré syndrome (GBS) are induced by molecular mimicry with cytomegalovirus (CMV).
BACKGROUND: Antibodies against ganglioside GM2 are frequently present in the serum from GBS patients with an antecedent infection with CMV.
METHODS: The authors detected inhibition of anti-GM2 reactivity after incubation of GM2-reactive serum samples with fibroblasts infected with a GBS-associated CMV strain. Control sera consisted of GQ1b-reactive samples, and control antigens included uninfected fibroblasts and fibroblasts that were infected with other herpes viruses.
RESULTS: Serum immunoglobulin M reactivity with GM2 was decreased in a dose-dependent manner after incubation with CMV-infected fibroblasts. Incubation of anti-GM2-positive serum samples with uninfected fibroblasts and fibroblasts infected with varicella zoster virus did not inhibit anti-GM2 reactivity, whereas this reactivity was slightly decreased after incubation with herpes simplex virus type 1 in one patient. Antibodies against ganglioside GQ1b did not react with CMV-infected fibroblasts.
CONCLUSIONS: CMV-infected fibroblasts express gangliosidelike epitopes that recognize specifically anti-GM2 antibodies. These results support the hypothesis that antiganglioside antibodies in CMV-infected GBS patients are induced by molecular mimicry between GM2 and antigens that are induced by a CMV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751257     DOI: 10.1212/wnl.54.7.1453

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.

Authors:  Michiaki Koga; Masaki Takahashi; Keiko Yokoyama; Takashi Kanda
Journal:  J Neurol       Date:  2015-06-09       Impact factor: 4.849

2.  Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.

Authors:  Joachim Schessl; Birgit Luther; Janbernd Kirschner; Gottfried Mauff; Rudolf Korinthenberg
Journal:  Eur J Pediatr       Date:  2006-05-12       Impact factor: 3.183

Review 3.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

4.  Guillain-Barré syndrome following hepatitis E.

Authors:  Jean Philippe Loly; Estelle Rikir; Maxime Seivert; Emile Legros; Pierre Defrance; Jacques Belaiche; Gustave Moonen; Jean Delwaide
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

5.  Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease.

Authors:  D L Mattey; P T Dawes; N B Nixon; L Goh; M J Banks; G D Kitas
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

6.  Guillain-Barré Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.972

7.  Idiopathic bilateral facial palsy: is a causative role of anti-GM1 ganglioside and herpes simplex type 1 possible?

Authors:  Elena Pretegiani; Francesca Rosini; Donatella Donati; Alessandra Rufa; Donatella Moschettini; Alfonso Cerase; Alessandra Morucci; Pasquale Annunziata; Antonio Federico
Journal:  Neurol Sci       Date:  2011-11-02       Impact factor: 3.830

Review 8.  SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms.

Authors:  Shahrzad Shoraka; Maria Lucia Brito Ferreira; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

9.  A Guillain-Barré syndrome variant with prominent facial diplegia.

Authors:  Keiichiro Susuki; Michiaki Koga; Koichi Hirata; Emiko Isogai; Nobuhiro Yuki
Journal:  J Neurol       Date:  2009-07-25       Impact factor: 6.682

10.  Lack of autoantibody production associated with cytomegalovirus infection.

Authors:  Beth C Marshall; Richard A McPherson; Eric Greidinger; Robert Hoffman; Stuart P Adler
Journal:  Arthritis Res       Date:  2002-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.